Painter Dan, Smith Alexandra, de Tute Ruth, Crouch Simon, Roman Eve, Jack Andrew
Epidemiology and Cancer Statistics Group, University of York, York, UK.
Haematological Malignancy Diagnostic Service, Leeds Cancer Centre Leeds, Leeds, UK.
Br J Haematol. 2015 Jul;170(2):175-8. doi: 10.1111/bjh.13412. Epub 2015 Apr 29.
This study investigates the value of performing a staging bone marrow in patients with diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and classical hodgkin lymphoma (CHL). The results of 3112 staging bone marrow examinations were assessed for impact on prognostic assessment and critical treatment decisions. The detection of marrow involvement altered the disease-specific prognostic index for 4·3% of DLBCL, 6·2% of FL and 0·6% of CHL but marrow involvement in DLBCL was an independent prognostic factor. Knowing the marrow status potentially changed treatment in 92 patients, detection of these patients would have required 854 examinations to be performed.
本研究调查了对弥漫性大B细胞淋巴瘤（DLBCL）、滤泡性淋巴瘤（FL）和经典霍奇金淋巴瘤（CHL）患者进行分期骨髓检查的价值。评估了3112例分期骨髓检查结果对预后评估和关键治疗决策的影响。骨髓受累的检测改变了4.3%的DLBCL、6.2%的FL和0.6%的CHL的疾病特异性预后指数，但DLBCL中的骨髓受累是一个独立的预后因素。了解骨髓状态可能改变了92例患者的治疗，检测出这些患者需要进行854次检查。
